Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 3
2010 1
2012 1
2013 1
2014 2
2015 3
2016 3
2017 2
2018 2
2019 5
2020 8
2021 8
2022 14
2023 17
2024 14
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.
Ruan DY, Huang WW, Li Y, Zhao Y, Shi Y, Jia Y, Cang S, Zhang W, Shi J, Chen J, Lin J, Liu Y, Xu J, Ouyang W, Fang J, Zhuang W, Liu C, Bu Q, Li M, Meng X, Sun M, Yang N, Dong X, Pan Y, Li X, Qu X, Zhang T, Yuan X, Hu S, Guo W, Li Y, Li S, Liu D, Song F, Tan L, Yu Y, Yu X, Zang A, Sun C, Zhang Q, Zou K, Dan M, Xu RH, Zhao H. Ruan DY, et al. Among authors: cang s. Signal Transduct Target Ther. 2025 Feb 28;10(1):62. doi: 10.1038/s41392-025-02155-5. Signal Transduct Target Ther. 2025. PMID: 40016191 Free PMC article. Clinical Trial.
OTUD7B is a new deubiquitinase targeting p53.
Ding C, Cao L, Wang R, Wu Q, Li M, Zhang J, Thorne RF, Li J, Ma J, Wu M, Cang S. Ding C, et al. Among authors: cang s. Theranostics. 2025 Jan 13;15(6):2121-2138. doi: 10.7150/thno.103012. eCollection 2025. Theranostics. 2025. PMID: 39990225 Free PMC article.
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study.
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A. Shi Y, et al. Among authors: cang s. Lancet Respir Med. 2025 Apr;13(4):327-337. doi: 10.1016/S2213-2600(24)00417-X. Epub 2025 Feb 3. Lancet Respir Med. 2025. PMID: 39914443 Clinical Trial.
Health-related quality of life and symptoms in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer treated with sintilimab or placebo plus pemetrexed and platinum (ORIENT-11): A randomized, double-blind, phase 3 trial.
Liu T, He J, Wang Y, Yang Y, Zhang L, Shi M, Liu J, Sun D, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Huang Y, Fang W, Yang Y, Zhao Y, Zhang L. Liu T, et al. Among authors: cang s. Lung Cancer. 2025 Feb;200:108108. doi: 10.1016/j.lungcan.2025.108108. Epub 2025 Jan 27. Lung Cancer. 2025. PMID: 39884222 Free article. Clinical Trial.
Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study.
Shi Y, Zhang Q, Wang J, Ouyang Z, Yi T, Mei J, Wang X, Pei Z, Sun T, Bai J, Cang S, Li Y, Fu G, Ma T, Shi H, Liu J, Wang X, Niu H, Guo Y, Zhou S, Sun L. Shi Y, et al. Among authors: cang s. Chin Med J (Engl). 2025 Feb 20;138(4):496-498. doi: 10.1097/CM9.0000000000003445. Epub 2025 Jan 17. Chin Med J (Engl). 2025. PMID: 39820410 Free PMC article. No abstract available.
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001).
Chen HJ, Tu HY, Hu Y, Fan Y, Wu G, Cang S, Yang Y, Yang N, Ma R, Jin G, Xu X, Liu A, Tang S, Cheng Y, Yu Y, Xu CR, Zhou Q, Wu YL. Chen HJ, et al. Among authors: cang s. J Hematol Oncol. 2025 Jan 5;18(1):3. doi: 10.1186/s13045-024-01656-0. J Hematol Oncol. 2025. PMID: 39757186 Free PMC article. Clinical Trial.
Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.
Huo Y, Wang D, Yang S, Xu Y, Qin G, Zhao C, Lei Q, Zhao Q, Liu Y, Guo K, Ouyang S, Sun T, Wang H, Fan F, Han N, Liu H, Chen H, Miao L, Liu L, Duan Y, Lv W, Liu L, Zhang Z, Cang S, Wang L, Zhang Y. Huo Y, et al. Among authors: cang s. J Immunother Cancer. 2024 Dec 19;12(12):e009627. doi: 10.1136/jitc-2024-009627. J Immunother Cancer. 2024. PMID: 39706602 Free PMC article.
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer.
Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Wu X, Yang J, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Wang H, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P. Jiang Z, et al. Among authors: cang s. Future Oncol. 2025 Feb;21(4):421-429. doi: 10.1080/14796694.2024.2430106. Epub 2024 Dec 4. Future Oncol. 2025. PMID: 39628303 Free PMC article.
Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.
Sun L, Xu Y, Chen N, Zhang C, Wu A, Wang H, Fei Y, Shu P, Diao D, Cheng J, Chu Y, Liu T, Wang W, Yuan Y, Zeng B, Cao Y, Cang S, Cao H, Zhang T, Zheng Y, Wu C, Liu S, He B, Yan Y, Yan S, Wu N, Ning C, Peng R, Epstein AS, Cytryn S, Mao JJ, Yang Y. Sun L, et al. Among authors: cang s. Eur J Cancer. 2024 Dec;213:115109. doi: 10.1016/j.ejca.2024.115109. Epub 2024 Nov 2. Eur J Cancer. 2024. PMID: 39509846 Clinical Trial.
88 results